In this article
Revolution Medicines
could be on the cusp of a breakthrough.
The company expects to soon release results from a Phase 3 trial of its experimental drug that could become the first targeted treatment for pancreatic cancer, the deadliest of the major cancers. Just 13% of people with pancreatic cancer live five years after they’re diagnosed, a number that hasn’t changed much despite the outlook for other cancers improving thanks to new drugs like immunotherapy. The possibility of a new treatment has buoyed RevMed’s stock by nearly 185% over the last year and made it a prime acquisition target.
“This is incredibly important,” said RBC Capital Markets analyst Leonid Timashev. “We’ve had physicians describe this as potentially the biggest breakthrough in pancreatic cancer ever.”
